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Subsequent malignant neoplasms (SMNs) devel-
oping after hematopoietic cell transplantation (HCT)
are a well-described complication [1-6]. The
magnitude of risk of SMNs after HCT ranges from
four-fold to 11-fold that of the general population.
The estimated actuarial incidence is reported to be
3.5% at 10 years, increasing to 12.8% at 15 years
among recipients of allogeneic HCT. The differing
clinicopathologic characteristics of SMNs preclude as-
sessment of risk factors in aggregate. It has become
conventional practice to classify SMNs into three dis-
tinct groups [7]: (1) myelodysplasia (t-MDS)/acute
myeloid leukemia (t-AML); (2) lymphoma, including
lymphoproliferative disorders; and (3) solid tumors.
Although t-MDS/AML and lymphoma develop rela-
tively early in the posttransplantation period, second-
ary solid tumors have a longer latency. The
magnitude of risk and associated risk factors for the de-
velopment of SMNs are summarized in Table 1 and
detailed in the following sections.MAGNITUDE OF RISKOF SUBSEQUENT
MALIGNANT NEOPLASM
Therapy-Related MDS/AML
The cumulative probability of developing t-MDS/
t-AML ranges from 1.1% to 24.3% at 20 to 43 months
after autologous HCT. In patients treated with alky-
lating agents, t-MDS/t-AML usually appears 4 to 7
years after exposure. The majority of patients present
with multilineage dysplasia and peripheral cytopenias.1Hematology Transplantation, APHP Hospital Saint
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6/j.bbmt.2011.10.005There is a high prevalence of abnormalities involving
chromosomes 5 (25/del[5q]) and 7 (27/del[7q]).
AML secondary to topoisomerase II inhibitors
presents as overt leukemia. The latency ranges from
6 months to 5 years and is associated with balanced
translocations involving chromosome bands 11q23 or
21q22.
The common and nonspecific nature of cytopenias
after autologous HCT has necessitated the creation of
criteria for diagnosing t-MDS/t-AML after HCT.
These include (1) significant marrow dysplasia in at
least two cell lines, (2) peripheral cytopenias without
alternative explanations, and (3) blasts in the marrow
defined by French-American-British classification
[8]. Because many patients may not have an increase
in blasts, presence of a clonal cytogenetic abnormality
in addition to morphologic criteria of dysplasia may
aid in making this diagnosis.
An increased risk of t-MDS/t-AML is associated
with older age at HCT [1], pretransplantation therapy
with alkylating agents, topoisomerase II inhibitors, and
radiation therapy [3], use of peripheral blood hemato-
poietic cells, stem cell mobilization with etoposide,
difficult stem cell harvests, conditioning with total-
body irridiation (TBI), number ofCD341 cells infused,
and a history of multiple transplants [1,3,9-11].
The diagnosis of t-MDS/t-AML after autologous
HCT confers a poor prognosis, with a median survival
of 6 months in patients treated with conventional che-
motherapy. In fact, t-MDS/t-AML is a major cause of
nonrelapse mortality in patients undergoing autolo-
gous HCT [3,12]. Allogeneic HCT has been
attempted with actuarial survival ranging from 0% to
24% at 3 years [13]. Among t-MDS/t-AML patients
with balanced aberrations, 11q23 translocations are
an independent adverse risk factor [14]. Treatment-
related mortality and relapse were reported to be
41% and 27% at 1 year and 48% and 31% at 5 years,
respectively, in a large cohort of patients undergoing
allogeneic HCT [15]. Disease-free and overall survival
rates were 32% and 37% at 1 year and 21% and 22% at
5 years, respectively. Age older than 35 years, poor-risk
cytogenetics, t-AML not in remission or advanced
t-MDS, and donor other than an HLA-identical sib-
ling or a partially or well-matched unrelated donor
had adverse impacts on disease-free survival andS139
Table 1. Magnitude of Risk and Populations at Increased Risk of Subsequent Malignant Neoplasms after Hematopoietic Cell Trans antation
Study Study Design Sample Size/Number of SMNs Primary Diagnoses; Type of HCT Magnitude of Risk and Risk Factors
All second malignant neoplasms
Witherspoon et al. N Engl J
Med. 1989;321:784-789 [7]
Retrospective cohort study 2,246/35 leukemia, lymphoma,
solid malignancies
Autologous or allogeneic HCT 6.7-fold increased sk compared with general population
Acute GVHD trea d with ATG or anti-CD3 antibody, TBI were associated
with increased k of SMN
Bhatia et al. Blood.
1996;87:3633-3639 [1]
Retrospective cohort study 2,150/53 leukemia, lymphoma,
solid malignancies
All hematologic malignancies, inborn
diseases of immune system
Autologous and allogeneic HCT
11.6-fold increase risk compared with general population
Cumulative proba lity: 9.9% at 13 years for all SMNs; 1.6% at 4
years for PTLD .6% at 13 years for solid malignancies. T cell depletion,
use of ATG, un lated donor HCT, primary immune deficiency
associated with creased risk of PTLD;
Deeg et al. Blood.
1996;87:386-392 [32]
Retrospective cohort 700/23 leukemias (ALL),
solid tumors and lymphomas
Severe aplastic anemia
Allogeneic HCT
Cumulative proba lity: 14% at 20 years
Azathioprine; diag sis of Fanconi anemia; irradiation and age at HCT in the
non-Fanconi co rt
Kolb et al. Ann Intern Med.
1999;131:738-744 [21]
Retrospective cohort study 1,036/53 leukemia,
lymphoma, solid malignancies
Leukemia, lymphoma, inborn
diseases of hematopoietic and
immune systems, severe
aplastic anemia
Autologous and allogeneic
Cumulative proba lity: 3.5% at 10 years;
3.8-fold increased sk compared with general population;
Older age at HCT nd treatment of cGVHD with cyclosporine associated
with increased k
Baker et al. J Clin Oncol.
2003;21:1352-1358 [22]
Retrospective cohort study 3,372/147 leukemia, lymphoma
and solid malignancies
All malignancies and metabolic
disorders; immune deficiency;
aplastic anemia
Autologous and allogeneic
8.1-fold increased sk compared with general population;
Cumulative incide e: 6.9% at 20 years for any malignancy; 1.4% at 10 years for
PTLD; 1.4% at 1 years for MDS/AML; 3.8% at 20 years for solid tumors
Posttransplantation
lymphoproliferative disorders
Landgren et al. Blood. 2009;113:
4992-5001 [16]
Retrospective cohort study 26,901/127 PTLD Hematologic malignancies and
severe aplastic anemia
Allogeneic HCT
T cell depletion, u of ATG, unrelated donor HLA-mismatched grafts.
Cumulative risk in eased to 8.1% with more than three risk factors
Curtis et al. Blood. 1999;94:
2208-2216 [17]
Retrospective cohort study 18,014/78 PTLD Hematologic malignancies
Allogeneic HCT
Cumulative incide e 1% at 10 years
Unrelated donor H T, T cell depletion, use of ATG, use of anti-CD3
monoclonal ant ody
Therapy-related MDS/AML
Krishnan et al. Blood.
2000;95:1588-1593 [3]
Retrospective cohort study
Nested case-control study
612/22 MDS/AML HL
NHL
Autologous HCT
Cumulative proba lity of MDS/AML: 8.6% at 6 years
Stem cell priming ith VP-16, pre-HCT radiation associated with increased
risk of t-MDS/A L
Milligan et al. Br J Haematol.
1999;106:1020-1026 [9]
Retrospective cohort design 4,998/66 MDS/AML HL
NHL
Autologous HCT
5-year cumulative obability was 4.6% for HL and 3% for NHL
Older age at HCT iagnosis of HL, exposure to TBI, multiple HCT, years
between diagno s were associated with increased risk of MDS/AML
Solid malignancies
Curtis et al. N Engl J Med.
1997;336:897-904 [2]
Retrospective cohort 19,229/80 solid malignancies Allogeneic HCT 2.7-fold increased sk of solid malignancies compared with the general
population
Cumulative incide e; 6.7% at 15 years; younger age at HCT associated with
increased risk o olid malignancies; chronic GVHD and male sex associated
with increased k of squamous cell carcinoma
Bhatia et al. J Clin Oncol.
2001;19:464-71 [20]
Retrospective cohort study 2,129/29 solid malignancies Hematologic malignancies
Autologous and allogeneic HCT
Two fold increased isk compared with general population
Cumulative proba lity: 6.1% at 10 years
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Rizzo et al. Blood.
2009;113:1175-1183 [4]
Retrospective cohort study 28,874/189 solid malignancies Hematologic malignancies and
hemoglobinopathies
Allogeneic HCT recipients
Two fold increased risk compared with general population
Chronic GVHD and male sex were associated with squamous cell carcinoma
Shimada et al. Bone Marrow
Transplant. 2005;36:115-21 [23]
Retrospective cohort study 809/19 solid malignancies All malignancies
Autologous and allogeneic HCT
2.8-fold increased risk
Cumulative incidence: 4.2% at 10 years;
Extensive cGVHD and older age were associated with increased risk
Gallagher et al. Cancer.
2007;109:84-92 [24]
Retrospective cohort study 926/28 solid malignancies Hematologic malignancies
Allogeneic HCT
10-year cumulative incidence:
3.1%;
1.85-fold increased risk compared with general population;
Older age at HCT and female donor associated with increased risk
Socie et al. Blood.
1991;78:277-279 [31]
Retrospective cohort 147/4 solid tumors Severe aplastic anemia/
allogeneic HCT
Cumulative probability: 22% at 8 years
Socie et al. J Clin Oncol.
2000;18:348-357 [33]
Retrospective cohort 3,182/25 solid tumors; 20 PTLD Acute leukemia in childhood Cumulative risk of solid tumors: 11% at 15 years;
Age <5 years at HCT; TBI were associated with increased risk of solid
tumors; cGVHD associated with decreased risk
Chronic GVHD, unrelated donor HCT, T cell-depleted graft, use of
ATG associated with increased risk of PTLD
Majhail et al. Blood.
2011;117:316-322 [35]
Retrospective cohort 4,318/66 solid cancers Acute myeloid leukemia;
Chronic myelogenous leukemia;
Allogeneic (matched related
and unrelated) HCT
Cumulative incidence: 1.2% at 10 years; 1.4-fold increased risk compared with
general population; chronic GVHD associated with increased risk,
sp oral cavity
Specific second malignant neoplasms
Rowlings et al. J Clin Oncol.
1999;17:3122-3127 [19]
Retrospective cohort 18,531/8 HL Hematologic malignancies
and severe aplastic anemia
Allogeneic HCT
6.2-fold increased risk;
Grade 2-4 acute GVHD, treatment for cGVHD
Leisenring et al. J Clin Oncol.
2006;24:1119-1126 [25]
Retrospective cohort
study design
4,180/237 nonmelanoma
skin cancer
All malignancies and
metabolic disorders
Allogeneic HCT
20-year cumulative incidence:
BCC: 6.5%; SCC: 3.4%
TBI and younger age at irradiation, light skin color, cGVHD associated with BCC
Acute and cGVHD associated with SCC
Curtis et al. Blood.
2005;105:3802-3811 [34]
Case-control 58 squamous cell and
125 basal cell carcinomas;
501 matched controls
Hematologic malignancies, severe
aplastic anemia,
emoglobinopathies; allogeneic
(matched related and unrelated)
HCT
Prolonged and severe chronic GVHD and its therapy (azathioprine,
corticosteroids, cyclosporine) were associated with squamous cell carcinomas
Schwartz et al. Radiat Res.
2009;171:155-163 [36]
Retrospective cohort 6,306/282 basal cell carcinomas Hematologic malignancies; severe
aplastic anemia; autologous,
matched related and unrelated
donor HCT
TBI exposure; youngest age at HCT; increasing attained age; whites; more recent
birth cohorts
Friedman et al. Blood.
2008;111:939-944 [5]
Retrospective cohort study 3,337 females/52
breast cancers
Hematologic malignancies
Allogeneic HCT
Cumulative incidence 11% at 25 years; longer time since HCT, use of TBI,
younger age at HCT
Cohen et al. J Clin Oncol.
2007;25:2449-2454 [6]
Retrospective
cohort study
78,914/32 thyroid cancer All malignancies and severe
aplastic anemia
Autologous and allogeneic
3.26-fold increased risk
Young age at HCT, irradiation, female sex, cGVHD
ATG indicates antithymocyte globulin; ALL, acute lymphoblastic leukemia; HL, Hodgkin leukemia; NHL, non-Hodgkin leukemia.
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S142 Biol Blood Marrow Transplant 18:S139-S150, 2012G. Socie et al.overall survival. Because the poor outcomes of alloge-
neic transplant for t-MDS/t-AML are related in part to
the high risk of treatment-related mortality, it is
important to evaluate the role of reduced-intensity
conditioning approaches in this setting. Preliminary
reports suggest that allogeneic HCT using reduced-
intensity conditioning is feasible and may result in
improved outcomes.
Posttransplantation Lymphoproliferative
Disorder
Posttransplantation lymphoproliferative disorder
(PTLD) is the most common SMN in the first year af-
ter allogeneic T cell-depleted HCT and is related to
a compromised immune status and Epstein-Barr virus
(EBV) infection [16,17]. The risk of PTLD is strongly
associated with T cell depletion of the donor marrow,
antithymocyte globulin use, unrelated or HLA
mismatched grafts, presence of acute or chronic
graft-versus-host disease (cGVHD), older age at
HCT, and multiple transplantations. The cumulative
incidence is 0.2% among patients with no major risk
factors but increased to 1.1%, 3.6%, and 8.1% with
one, two, and .three risk factors, respectively. The
large majority of the PTLDs have a B cell origin.
Therapeutic approaches include B cell-specific mono-
clonal antibodies, and cellular therapy. The efficacy of
anti-CD20 monoclonal antibody (rituximab) in the
treatment of PTLD has been reported. The drug is
more efficacious in patients without mass lesions,
forming the basis for recommendations to initiate
treatment at an early stage, based on increasing EBV
load. Because EBV-associated PTLD results from T
cell dysfunction, reconstitution of ‘‘at-risk’’ patients
with EBV-specific cytotoxic T-lymphocyte lines reac-
tivated and expanded in vitro has been shown to be
efficacious in controlling PTLD, with a decrease in
the EBV DNA concentrations and clinical remission.
Late-occurring lymphoma is distinct from the
early-occurring PTLD [18] and is associated with
extensive cGVHD. Hodgkin lymphoma has also
been described after HCT [19]. Mixed cellularity is
the most commonly reported subtype, and most of
the cases contain the EBV genome. These cases differ
from the EBV-PTLD by the absence of risk factors
commonly associated with EBV-PTLD, by a later
onset (.2.5 years), and a relatively good prognosis.
Solid Tumors
Solid tumors develop after syngeneic, allogeneic,
and autologous HCT. The reported cumulative inci-
dence of solid cancers following allogeneic SCT
ranges from 1.2% to 1.6% at 5 years, 2.2% to 6.1%
at 10 years, and from 3.8% to 14.9% at 15 years post-
transplantation [1,2,4,20-24]. There is no evidence for
any plateau in the incidence rate [4]; rather, the slopeof the curve continues to show a steadily increased in-
cidence with increased follow-up. Radiation is the sin-
gle most important risk factor for the development of
solid tumors. These radiogenic cancers have a long la-
tent period, and the risk is frequently high among pa-
tients undergoing irradiation at a young age.
Immunologic alterations may predispose patients to
SCC of the buccal cavity, particularly in view of the as-
sociation with cGVHD [25]. In immunosuppressed
patients, oncogenic viruses such as human papilloma-
virus may contribute to squamous cell carcinoma
(SCC) of the skin and buccal mucosa after transplanta-
tion [25]. Types of solid tumors reported in excess
among HCT recipients include melanoma, cancers
of the oral cavity and salivary glands, brain, liver, uter-
ine cervix, thyroid, breast, bone, and connective tissue
[2,4]. Second solid tumors represent an important
cause of nonrelapse-related death in patients who
survive more than 2 to 5 years posttransplantation
accounting for 5% to 10% of late deaths [26-30].
The following sections describe the magnitude of
risk of second solid tumors from single-institution
studies, as well as large collaborative initiatives.Single-center studies
In the first larger series, analyzing results in 2,145
patients who underwent transplantation from 1970 to
1987 in Seattle, Witherspoon et al. [7] found 35 new
malignancies, including 13 solid tumors. TBIwas a sig-
nificant risk factor when all malignancies were consid-
ered. Subsequent analysis of the results in patients with
aplastic anemia who underwent transplantation in
Seattle and at Hospital Saint Louis in Paris [31,32] as
well as reports from other American and European
centers [21,29] showed that irradiation was
a significant risk factor. A combined analysis of
results in 700 patients with aplastic anemia who
underwent transplantation at the Fred Hutchinson
Cancer Research Center (FHCRC) or Hospital Saint
Louis [32] suggested that in addition to irradiation
(relative risk [RR], 3.9) treatment of cGVHDwith aza-
thioprine (RR, 7.5) and older age (RR, 1.1) increased
the risk of a posttransplantation malignancy. Not sur-
prisingly, the highest incidence of malignancy was ob-
served in patients in whom the etiology of marrow
failure was Fanconi anemia. Bhatia and colleagues [1]
summarized the Minneapolis results: among 2,150 pa-
tients, 15 developed a solid tumor (eight in 1,400 allo-
geneic and seven in 750 autologous transplant
recipients) for a cumulative probability of 5.6% at 13
years. Again, irradiation was the major risk factor
(RR, 6; P5 .008). The role of pretransplantation treat-
ment was also examined by Bhatia and coworkers in
another study; [20] patients who had undergone stem
cell transplantation (SCT) at the City of Hope
National Medical Center between 1976 and 1998
Biol Blood Marrow Transplant 18:S139-S150, 2012 S143SMNs after HCTwere studied. A retrospective cohort and nested case-
control study design were used to evaluate the role of
pretransplantation therapeutic exposures and trans-
plantation conditioning regimens. Twenty-nine
patients developed solid cancers after bone marrow
transplantation, which represents a two fold increase
in risk compared with a comparable normal popula-
tion. The estimated cumulative probability for devel-
opment of a solid cancer was 6.1% 6 1.6% at
10 years. This largely confirms previous results. How-
ever, no significant factor emerged from the nested
case-control study used to evaluate the role of pre-
transplantation therapeutic exposures.
Collaborative studies
The relative paucity of cases rapidly pointed out
the critical need for collaborative studies. In an inter-
national effort, the Center for International Blood
and Marrow Transplant Research, the National Insti-
tutes of Health, and the FHCRC in Seattle launched
such collaborative studies. In the first one, Curtis
et al. [2] analyzed results in 19,220 patients (97.2%
allogeneic, 2.8% syngeneic recipients) who underwent
transplantation between 1964 and 1992 at 235 centers.
There were 80 solid tumors for an observed/expected
(O/E) ratio of 2.7. The cumulative incidence of tumors
was 2.2% at 10 years and 6.7% at 15 years. The risk was
increased significantly for melanoma (O/E 5 5.0),
cancers of the buccal cavity (O/E 5 11.1), liver
(O/E5 7.5), central nervous system (O/E5 7.6), thy-
roid (O/E 5 6.6), bone (O/E 5 13.4), and connective
tissue (O/E 5 8.0). The risk was highest for the youn-
gest patients and declined with age (P for trend\.001).
The risk associated with TBI declined if irradiation
was given with a fractionation regimen but increased
with the total cumulative dose administered.
Because the risk was the highest in youngest pa-
tients, the National Institutes of Health/International
Bone Marrow Transplant Registry and FHCRC re-
search group then analyzed a cohort of children who
underwent transplantation for leukemia [33]. A cohort
of 3,182 children diagnosed with acute leukemia be-
fore the age of 17 years who received allogeneic SCT
between 1964 and 1992 at 235 centers was studied.
Cumulative risk of solid cancers increased sharply to
11.0% at 15 years and was highest among children at
ages younger than 5 years at transplantation. Thyroid
and brain cancers (n 5 14) accounted for most of the
strong age trend; many of these patients received cra-
nial irradiation before HCT.
A case-control study of 183 patients with post-
transplantation solid cancers (58 SCCs, 125 non-
SCCs) and 501 matched control patients within a
cohort of 24,011 patients was conducted [34]. Results
showed that cGVHD and its therapy were strongly
related to the risk for SCC, whereas no increase in
risk was found for non-SCCs. Major risk factors forthe development of SCC were long duration of
cGVHD therapy, use of azathioprine, particularly
when combined with cyclosporine and steroids, and
severe cGVHD.
Because in the first National Institutes of Health/
International Bone Marrow Transplant Registry and
FHCRC study, relatively few patients surviving more
than 10 years post-SCT were included, we have contin-
ued surveillance of these and other SCT survivors to
determine whether solid cancer risk changed beyond
10 years after transplantation [4]; 189 new cancers
were found in 28,874 allogeneic SCT recipients. The
average age at transplantation was 27 years, and 67%
of patients received TBI as part of their preparative reg-
imen.The cumulative incidence of invasive solid cancers
for all patients was 2.2% 6 0.4% at 10 years, 5.0% 6
1.2% at 15 years, and 8.1% 6 3.1% at 20 years. New
findings showed that the risk of developing a non-SCC
following conditioning radiation was highly dependent
onage at exposure.Amongpatients irradiated at agesun-
der 30 years, the relative risk of non-SCCwas nine times
that of nonirradiated patients, whereas the comparable
risk for older patients was 1.1. Chronic GVHD and
male sex were the main determinants for risk of SCC.
Siteswith significantly (P\.05) increased risksof second
cancers after transplantation were oral cavity (O/E 5
11.6), salivary glands (O/E 5 14.2), liver (O/E 5 6.9),
skin (O/E 5 4.2), brain (O/E 5 6.0), thyroid (O/E 5
6.3), and bone/connective tissue (O/E 5 8.4). A new
finding in this study, not seen in previous reports, is
a significantly increased risk of breast cancer among
10-year survivors (O/E5 3.3 with five observed cases).
Finally, risks of secondary solid cancers among al-
logeneic SCT recipients who receive conditioning
without TBI were not well known. We thus evaluated
the incidence and risk factors for solid cancers after
HCT using high-dose busulfan-cyclophosphamide
conditioning in 4,318 recipients of first allogeneic
HCT for AML in the first complete remission and
chronic myeloid leukemia in the first chronic phase
(N 5 2,576) [35]. Our cohort represented 22,041
person-years at risk. Sixty-six solid cancers were re-
ported at a median of 6 years after HCT. The
cumulative incidence of solid cancers at 5 and 10 years
after HCT was 0.6% and 1.2% among acute myeloid
leukemia and 0.9% and 2.4% among chronic myeloid
leukemia patients. In comparison to general population
incidence rates, HCT recipients had 1.4-fold higher-
than- expected rate of invasive solid cancers. Recipients
of allogeneic HCT using busulfan and cyclophospha-
mide conditioning are at risk for developing solid can-
cers. For the first time, an excess risk of lung cancers
was found in long-term survivors after SCT.
The magnitude of risk and associated risk factors
for some of the more commonly occurring second
solid tumors among HCT recipients are detailed
in the information to follow.
S144 Biol Blood Marrow Transplant 18:S139-S150, 2012G. Socie et al.Skin cancer
The 20-year cumulative incidence of basal cell car-
cinoma (BCC) and SCC are reported to be 6.5% and
3.4%, respectively, after allogeneic HCT [25]. TBI is
a risk factor of BCC particularly among patients youn-
ger than 18 years old at HCT. Acute GVHD increased
the risk of SCC; cGVHD increased the risk of BCC
and SCC [36].
Breast cancer
The 25-year cumulative incidence of breast cancer
is reported to be 11% after allogeneic HCT [5]. Allo-
geneic HCT survivors are at a 2.2-fold increased risk
of developing breast cancer, when compared with an
age- and sex-matched general population. The median
latency fromHCT to diagnosis of breast cancer is 12.5
years. The incidence is higher among those exposed to
TBI (17%) than among those who did not receive TBI
(3%).The risk is increased among those exposed to
TBI at a younger age.
Thyroid cancer
Cohen et al described the risk of thyroid cancer af-
ter HCT. HCT recipients were at a 3.3-fold increased
risk of thyroid cancer, when compared with an age-
and sex-matched general population [6]. Age younger
than 10 years at HCT, neck radiation, female sex,
and cGVHD were associated with an increased risk
of thyroid cancer. Thyroid cancer developed after a la-
tency of 8.5 years in this cohort and was associated with
an excellent outcome.PATHOGENESIS OF SMNS AFTER HCS
The magnitude of association between specific
chemotherapeutic agents or radiation and SMNs is
moderate to large (odds ratio [OR], 3.1-15.9), with
a clear dose-response relationship adding further bio-
logical credibility to this association. The risk of sec-
ond breast cancer after chest radiation increases in
a linear fashion with radiation dose (P for trend
\.001) [37,38], as does the risk for second brain
tumors and second sarcomas [39]. Literature clearly
supports the role of chemotherapy and radiation in
the development of SMNs [40], but interindividual
variability suggests a role for genetic variation in sus-
ceptibility to genotoxic exposures. The risk of SMNs
could potentially be modified by mutations in high-
penetrance genes that lead to serious genetic diseases,
for example, Li-Fraumeni syndrome [41] and Fanconi
anemia [42,43]. However, attributable risks are
expected to be very small because of their extremely
low prevalence. The interindividual variability in risk
of therapy-related SMNs is more likely related to com-
mon polymorphisms in low-penetrance genes that reg-
ulate the availability of active drug metabolite or thoseresponsible for DNA repair. Genetic variation con-
tributes 20% to 95% of the variability in cytotoxic
drug disposition [44]. Polymorphisms in genes in-
volved in drug metabolism and transport are relevant
in determining disease-free survival and drug toxicity
[45]. Variation in DNA repair plays a role in suscepti-
bility to de novo cancer [46-50] and likely modifies
SMN risk after exposure to DNA-damaging agents,
such as radiation and chemotherapy. Gene–environ-
ment interactions may magnify subtle functional dif-
ferences resulting from genetic variations [51-54].Drug Metabolism
Metabolism of genotoxic agents occurs in two
phases. Phase I involves activation of substrates into
highly reactive electrophilic intermediates that can
damage DNA—a reaction principally performed by
the cytochrome p450 (CYP) family of enzymes. Phase
II enzymes (conjugation) function to inactivate geno-
toxic substrates. The phase II proteins comprise the
glutathione S-transferase (GST), NAD(P)H:quinone
oxidoreductase-1, and others. The balance between
the two sets of enzymes is critical to the cellular re-
sponse to xenobiotics; for example, high activity of
phase I enzyme and low activity of a phase II enzyme
can result in DNA damage from the excess of harmful
substrates. Given that these enzymes activate/detoxify
chemotherapeutic agents—their role in the develop-
ment of SMNs applies mainly to t-MDS/AML. The
xenobiotic substrates of CYP proteins include cyclo-
phosphamide, ifosfamide, thiotepa, doxorubicin, and
dacarbazine [55]. The CYPs transfer singlet oxygen
onto their substrates creating highly reactive interme-
diates, which, unless detoxified by phase II enzymes,
have a strong ability to damage DNA [56]. The expres-
sion of these enzymes is highly variable among individ-
uals because of several functionally relevant genetic
polymorphisms. GSTs detoxify reactive electrophiles
via conjugation to reduced glutathione, preventing
damage to DNA. Polymorphisms exist in cytosolic
subfamilies: m [M], p [P), q [T], and others. GSTs de-
toxify doxorubicin, lomustine, busulfan, chlorambucil,
cisplatin, cyclophosphamide, melphalan, etc. [57].
Quinone oxidoreductase NAD(P)H:quinone
oxidoreductase-1 uses the cofactors NADH and
NADPH to catalyze the electron reduction of its sub-
strates, produces less-reactive hydroquinones, and
therefore, prevents generation of reactive oxygen spe-
cies and free radicals that may subsequently lead to ox-
idative damage of cellular components. Allan et al. [58]
utilized a candidate gene approach to examine associ-
ations between polymorphisms in the glutathione
S-transferase genes (GSTM1, GSTT1, and GSTP1)
and t-MDS/AML. A case-control study design was
used (80 cases; 420 patients with de novo AML;
1,022 healthy controls). Individuals with at least one
Biol Blood Marrow Transplant 18:S139-S150, 2012 S145SMNs after HCTGSTP1 codon 105 Val allele were significantly over-
represented in t-AML cases compared with de novo
AML cases (OR, 1.81; 95% confidence interval [CI],
1.11-2.94). Also, relative to de novo AML, the
GSTP1 codon 105 allele occurred more often among
t-AML patients with prior exposure to chemotherapy
(OR, 2.66; 95% CI, 1.39-5.09), particularly among
those with prior exposure to known GSTP1 substrates
(OR, 4.34; 95% CI, 1.43-13.20) and not among t-
AML patients with exposure to radiation alone.DNA Repair
DNA repair mechanisms protect somatic cells
from mutations in tumor suppressor genes and onco-
genes that can lead to cancer initiation and progres-
sion. An individual’s DNA repair capacity appears to
be genetically determined [59]. A number of DNA re-
pair genes contain polymorphic variants, resulting in
large interindividual variations in DNA repair capacity
[59]. Even subtle differences in an individual’s DNA
repair capacity may be important in the presence of
large external influences such as chemotherapy or ra-
diotherapy. Individuals with altered DNA repair
mechanisms are likely susceptible to the development
of genetic instability that drives the process of carcino-
genesis as it relates to both chemotherapy-related
t-MDS/AML as well as radiation-related solid SMNs.
Mismatch repair (MMR) functions to correct mis-
matched DNA base pairs that arise as a result of misin-
corporation errors that have avoided polymerase
proofreading during DNA replication [60]. Defects
in the MMR pathway result in genetic instability or
a mutator phenotype, manifested by an elevated rate
of spontaneous mutations characterized as multiple
replication errors in simple repetitive DNA sequences
(microsatellites)—functionally identified as microsa-
tellite instability. Approximately 50% of t-MDS/
AML patients have microsatellite instability, associ-
ated with methylation of the MMR family member
MLH1 [61,62], low expression of MSH2 [63], or poly-
morphisms in MSH2 [64-66]. The appearance of
MMR-deficient, drug-resistant clones during geno-
toxic treatment for a primary cancer could be a vital
factor in SMN susceptibility, particularly because the
mutator phenotype (inherent of MMR-deficient cells)
would be expected to accelerate the accumulation of
further mutations and eventually SMN initiation. In
addition, loss of MMR may result in deregulation of
homologous recombination repair and consequent
chromosomal instability [67].
Double-strand breaks (DSBs) in DNA may lead to
loss of genetic material, resulting in chromosomal ab-
errations. High levels of DSBs arise following ionizing
radiation and chemotherapy exposures. Cellular path-
ways available to repair DSBs include homologous
recombination (HR), nonhomologous end-joining,and single-strand annealing [68]. HR uses the second,
intact copy of the chromosome as a template to copy
the information lost at the DSB site on the damaged
chromosome—a high-fidelity process. RAD51 is one
of the central proteins in the HR pathway, functioning
to bind to DNA and promote adenosine triphosphate-
dependent homologous pairing and strand transfer
reactions [69,70]. RAD51-G-135C polymorphism is
significantly overrepresented in patients with
t-MDS/AML compared with controls (C allele: OR,
2.7) [71]. XRCC3 also functions in the HRDSB repair
pathway by directly interacting with and stabilizing
RAD51 [72,73]. XRCC3 is a paralog of RAD51, also
essential for genetic stability [74,75]. The variant
XRCC3-241Met allele has been associated with
a higher level of DNA adducts compared with cells
with the wild-type allele, implying aberrant repair
[76] and has also been associated with increased levels
of chromosome deletions in lymphocytes after expo-
sure to radiation [77]. Although XRCC3-Thr241Met
was not associated with t-MDS/AML (OR, 1.4; 95%
CI, 0.7-2.9), a synergistic effect resulting in an eight
fold increased risk of t-MDS/AML (OR, 8.1; 95%
CI, 2.2-29.7) was observed in the presence of
XRCC3-241Met and RAD51-135C allele in patients
with t-MDS/AML compared with controls [71]. Non-
homologous end-joining pathway joins broken DNA
ends containing very little homology. This process is
not always precise and can result in small regions of
nontemplate nucleotides around the site of the DNA
break, potentially relevant in MLL translocation asso-
ciated with t-MDS/AML.
Base excision repair pathway corrects individually
damaged bases occurring as a result of ionizing radia-
tion and exogenous xenobiotic exposure. The XRCC1
protein plays a central role in the base excision repair
pathway and also in the repair of single-strand breaks,
by acting as a scaffold and recruiting other DNA repair
proteins [78,79]. The protein also has a BRCA1
C-terminus domain—a characteristic of proteins
involved in DNA damage recognition and response.
The presence of variant XRCC1-399Gln has been
shown to be protective for t-MDS/AML [80] and
BCC [81].
Nucleotide excision repair (NER) removes struc-
turally unrelated bulky damage induced by radiation
and chemotherapy. The NER pathway is linked to
transcription, and components of the pathway com-
prise the basal transcription factor IIH complex, which
is required for transcription initiation by RNA poly-
merase II. One of the genes involved in the NER path-
way (ERCC2) is a member of the transcription factor
IIH complex. The polymorphic Gln variant (ERCC2
Lys751Gln) is associated with t-MDS/AML [52].
A proposed mechanism of the pathogenesis of
therapy-related SMNs is illustrated in Figure 1.
Several studies have attempted to understand the
Figure 1. Therapy-related SMN—hypothesized mechanisms for
genetic susceptibility.
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encompass both children and adults, treated with
conventional therapy, as well as with HCT. They are
summarized in the following sections.
Ellis et al. [82] utilized a case-control study design
(171 cases) and examined the association between pa-
tients with t-MDS/AML and two common functional
p53-pathway variants—the MDM2 SNP309 and the
TP53 codon 72 polymorphism.Neither polymorphism
demonstrated a significant association. However, an
interactive effect was detected such that MDM2 TT
TP53 Arg/Arg double homozygotes and individuals
carrying both anMDM2G allele and a TP53 Pro allele
were at increased risk of chemotherapy-related
t-MDS/AML. The strengths of the study included
the utilization of a discovery (n5 80 case) and replica-
tion set (n5 91 cases). However, the investigators uti-
lized healthy controls as a comparison group—thus
precluding the ability to assess whether the case-
control differences reflected differences in susceptibil-
ity to primary disease or t-MDS/AML.
Knight et al. [83] used a case-control study design
to conduct a genome-wide association study in pa-
tients who had developed therapy-related leukemia
(cases) and healthy controls [83]. The discovery set in-
cluded 80 cases and 150 controls. The relevant find-
ings were replicated in an independent set of 70 cases
and 95 controls. The investigators identified three
single-nucletide polymorphisms (rs1394384 [OR,
0.29; 95% CI, 0.15-0.56], rs1381392 [OR, 2.08; 95%
CI, 1.29-3.35], and rs1199098 [OR, 0.46; 95% CI,
0.27-0.79]) to be associated with t-MDS/AML with
chromosome 5/7 abnormalities. rs1394384 is intronic
toACCN1, a gene encoding an amiloride-sensitive cat-
ion channel that is a member of the degenerin/epithe-
lial sodium channel; rs1199098 is in LD with IPMK,
which encodes a multikinase that positively regulates
the prosurvival AKT kinase and may modulate Wnt/
b-catenin signaling; rs1381392 is not near any known
genes, miRNAs, or regulatory elements, although it
lies in a region recurrently deleted in lung cancer.
Although the investigators were able to confirm find-ings in an independent replication cohort, the utiliza-
tion of a noncancer healthy control group raises
concerns about the case-control differences being
generated by the genetics of the primary cancer versus
t-MDS/AML.
Best et al. [84] performed a genome-wide associa-
tion study to identify variants associated with
radiation-related solid malignancies in survivors of
Hodgkin lymphoma. They identified two variants at
chromosome 6q21 associated with second malignan-
cies. The variants comprise a risk locus associated
with decreased basal expression of PRDM1 and im-
paired induction of the PRDM1 protein after radiation
exposure. These data suggest new gene-exposure
interaction that may implicate PRDM1 in the etiology
of radiation therapy-induced second malignancies.BURDEN OF MORBIDITY FROM
SUBSEQUENT MALIGNANT NEOPLASMS
AFTER HCT
As indicated in the previous sections, SMNs are
amajor factor contributing to the long-termmorbidity
and mortality experienced by survivors after HCT. In
data reported from the Bone Marrow Transplant Sur-
vivor study, survivors after allogeneic HCT have a risk
of premature death that is nearly 10-fold higher com-
pared with the general population [30]. Although re-
lapse of the primary disease (29%), cGVHD (22%),
and late infection in the absence of cGVHD (11%)
were the three leading causes of death occurring 2 or
more years after HCT, subsequent malignancy was the
leading cause of late mortality because of treatment-
related causes and accounted for 7% of deaths. A
similar analysis in survivors after autologous HCT
also found a significantly higher risk for premature
death (standardized mortality ratio 513 compared
with the general population). Although the majority
of deaths were attributed to relapse of the primary dis-
ease, 25% were because of SMNs [12]. Recent data
from the Seattle group replicated these findings, where
recurrent disease (19%) and subsequent malignancies
(26%) were the two leading causes of death, represent-
ing over a four fold-higher risk of death related to
post-HCT solid tumors [28]. In this study, SMNs
represented a higher percentage of total deaths, likely
related to the longer follow-up in the Seattle cohort.
Although mortality related to SMNs is quantifiable,
the morbidity related to a diagnosis of an SMN in
HCT survivors has never been adequately ascertained.
Many patients have been very heavily treated before
HCT and have received myeloablative doses of che-
motherapy and/or TBI. The tolerability of standard
treatment approaches for SMNs is questionable, and
the additional organ toxicity and other therapy-
related side effects can have significant impact on the
quality of life of survivors. Little data are available on
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ever, in data reported from the University of Minne-
sota, HCT survivors who developed a subsequent
solid tumor had a survival at 5 years of 44% with a me-
dian survival time of 1.9 years. For patients with
t-MDS/AML after autologous HCT, the median sur-
vival was 303 days, and survival at 1 year after diagnosis
was 34% [22].Genetic  
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Figure 2. Long-term risk-reduction strategies.SCREENING FOR SMNS IN HCT SURVIVORS
There is paucity of data regarding the clinical de-
tails at presentation of SMNs, in particular, the clinical
stage. Theoretically, if screening practices resulted in
subsequent cancers being diagnosed at an earlier stage
at the time of presentation, then treatment would be
more successful and survival rates higher. Additionally,
less aggressive treatment may be required, resulting in
less toxicity. The issue of who to screen, how to screen,
and when to do it, are all important but largely unan-
swered questions. For the pediatric survivor popula-
tion, the Children’s Oncology Group has developed
comprehensive long-term follow-up guidelines that
provide risk-adapted recommendations based on ther-
apeutic exposures and that are supported by the best
available published literature [85]. For the HCT survi-
vors, screening recommendations must incorporate
risks associated with pre-HCT therapy as well from
the transplantation conditioning therapy and other
HCT-associated conditions such as cGVHD. Joint
recommendations for screening and preventative prac-
tices for long-term survivors after HCT from the Eu-
ropeanGroup for Blood andMarrowTransplantation,
the Center for International Blood and Marrow
Transplant Research, and the American Society of
Blood and Marrow Transplant were published in
2006 [86]. This reference provides general guidance
for SMN screening for HCT survivors, but recom-
mendations are limited to annual risk awareness coun-
seling and clinical assessments. General
recommendations for colorectal, breast, and cervical
cancer are provided, but are for the most part, based
on guidelines for the general population. Screening
guidelines developed for use in the general population
may or may not be sufficient or applicable for use in
HCT survivors. For some individuals, additional risk
factors either pre-HCT (exposure to chest radiation,
cranial radiation, alkylating agents, topoisomerase II
inhibitors) or associated with HCT (TBI, cGVHD,
duration of immunosuppression, T cell depletion)
[2,4,21,22,32,33,87] may lead to elevated risks and
must be considered in the screening strategies.
Recently, published single-institution data found that
75% of HCT survivors were adhering to recommen-
ded preventive care guidelines, which is higher than re-
ported for the general population by the National
Center for Health Statistics. In addition, rates of ad-herence to specialized cancer screening testing were
high, including 82% for colonoscopy or sigmoidos-
copy, 84% for Pap smear, and 90% for mammography
[88]. Although the median follow-up after HCT was
11 years, 76% of respondents reported seeing their
physician at least once in the past 3 months, and thus
it may not be too surprising that adherence rates
were high in this cohort. Lower adherence rates were
associated with autologous HCT, concerns about
medical costs, an interval of .15 years since HCT,
non-White race, male sex, lower physical functioning,
and absence of cGVHD.RISK-REDUCTION STRATEGIES
Risk-reduction strategies need to use a multi-
pronged approach, as detailed in Figure 2. Thus, al-
though strategies aimed at altering therapeutic
exposures (chemotherapy and radiation) will most
likely result in a reduction in the risk of subsequent
malignancies in some patients, it is unlikely that these
exposures are the only factors that convey risk. In fact,
it has been very well documented that recipients of
solid organ allografts who subsequently require life-
long immunosuppression, also have a higher risk of
developing malignancies presumably secondary
to altered immune surveillance [89-91]. In HCT
recipients, the risk of SMNs is associated with
duration of immunosuppression and also to cGVHD
(likely from ongoing immunosuppression as opposed
to an impact of GVHD itself), thus delayed immune
recovery or persistent immunodeficiency may
contribute to the risk of subsequent malignancy after
HCT as well [2,21]. Efforts to prevent GVHD and
to improve immune reconstitution after HCT may
be an effective strategy to reduce the risk of
subsequent malignancy.
There is increasing concern related to the risk of
cancer and cancer death associated with obesity and
S148 Biol Blood Marrow Transplant 18:S139-S150, 2012G. Socie et al.a sedentary lifestyle [92,93]. Functional and
performance limitations and lower levels of physical
activity have been reported in HCT survivors,
particularly in those who have cGVHD [94-96].
Obesity (as determined by body mass index) is
uncommon in HCT survivors [97]; however, prelimi-
nary studies of body composition reveal that they have
a high percentage of fat mass and a reduction in muscle
mass. This state of sarcopenic obesity contributes to
the development of insulin resistance, hyperinsuline-
mia, and chronic inflammation—factors that have
been implicated in the causal pathway of obesity-
associated cancer risk [98]. Thus, interventions recom-
mended for the general population aimed at improving
nutrition and maintaining a physically active lifestyle
are likely of even greater significance for HCT survi-
vors as preventative measures for development of
SMNs. Finally, as the pathogenesis of SMNs becomes
more clearly elucidated, screening for known genetic
susceptibility to cancer could possibly be undertaken
and alternative therapeutic options presented to the
vulnerable subpopulation. These strategies, as well as
those encouraged for all, such as avoidance of tobacco
and alcohol, use of sunscreen, and HPV vaccination,
may help to reduce the risk of SMNs in HCT survi-
vors. Additionally, providing education to our survi-
vors in order to raise awareness of the risk of SMNs
and also to the primary care community whowill be in-
volved with the long-term follow-up and screening of
these individuals will be very important.ACKNOWLEDGMENT
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